JEWISH TIME PODCAST JEWISH TIME PODCAST SUBSCRIBE TODAY SUBSCRIBE TODAY
search
Gilead Sciences Inc.
In this photo one vial of the drug Remdesivir is viewed during a press conference about the start of a study with the Ebola drug Remdesivir in particularly severely ill patients at the University Hospital Eppendorf (UKE) in Hamburg, northern Germany on April 8, 2020, amidst the new coronavirus COVID-19 pandemic. - Gilead Science's remdesivir, one of the most highly anticipated drugs being tested against the new coronavirus, showed positive results in a large-scale US government trial, the company said on April 29, 2020."We understand that the trial has met its primary endpoint and that NIAID (National Institute of Allergy and Infectious Diseases) will provide detailed information at an upcoming briefing," the company said. (Photo by Ulrich Perrey / POOL / AFP)
May 4, 2020, 7:21 am
Remdesivir Results for Virus Encouraging but too Early to Celebrate
FDA last week gave emergency approval to medicine produced by Gilead Sciences; it is believed to shorten illness time in some, but effect on mortality rates still unclear.
By TOI Staff and AP
Load More